TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33569574
Drug: Intensive anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive anti-hypertensive therapy
Study: 35158064
Drug: 7-day preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day preoperative application of benzoyl peroxide-miconazole nitrate cream
Study: 32747206
Drug: Intravenous meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meal administration
Study: 35968751
Drug: Dexmedetomidine 0
Normalized name: dexmedetomidine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0 μg/kg (Control group)
Study: 35968751
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 μg/kg (D1 group)
Study: 34959932
Drug: Astaxanthin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (12 mg once daily for 12 weeks)
Study: 33005007
Drug: Maternal SO2
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal SO2 exposure (per 10 μg/m3 increase)
Study: 33020985
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy-enhanced cognitive behavioural therapy for insomnia
Study: 36084965
Drug: allo‐hBM‐MSCDs (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: allo‐hBM‐MSCDs (1 mL, 2 doses)
Study: 36084965
Drug: allo‐hBM‐MSCs (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: allo‐hBM‐MSCs (1 × 10^6 cells, 1 dose)
Study: 33278328
Drug: JZP-458 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: JZP-458 (25 mg/m2 i.m. and 37.5 mg/m2 i.v.)
Study: 33278328
Drug: JZP-458 (i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: JZP-458 (i.m. injection)
Study: 33278328
Drug: JZP-458 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: JZP-458 (all dose levels)
Study: 37646208
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers (ARBs)
Study: 35491539
Drug: Single ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose of Youkenafil Hydrochloride (25, 50, 100, 150, or 200 mg)
Study: 39675376
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy
Study: 32379556
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (O3T)
Study: 35156936
Drug: Weekly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly monitoring
Study: 33975925
Drug: CALLS intervention
Normalized name: Mosco Corn & Callus Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALLS intervention (12-weekly phone sessions with patient navigator)
Study: 36174629
Drug: Niraparib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib plus ipilimumab (3 mg/kg intravenously every 3 weeks for four doses)
Study: 34991364
Drug: Proposed interventional
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed interventional treatment in a double-blinded, randomized, placebo-controlled clinical trial
Study: 32633040
Drug: 2-mm inter-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mm inter-implant distance
Study: 35351381
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg)
Study: 34910380
Drug: BSC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSC plus a moisturising cream
Study: 33149205
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg/day for three consecutive days
Study: 32486104
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Etoricoxib + exercise)
Study: 32613089
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment only
Study: 33051719
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid infiltrated tumescent solution (0.1%)
Study: 34933842
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of full-spectrum hyaluronan (FS-HA)
Study: 36344917
Drug: Bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine + 1 µg/kg dexmedetomidine
Study: 36344917
Drug: Bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine + 1 µg/kg fentanyl
Study: 39340109
Drug: All vaccines
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccines
Study: 34984792
Drug: Omalizumab 300
Normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 300 mg (OMA300)
Study: 34984792
Drug: Omalizumab 150
Normalized name: omalizumab 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 150 mg (OMA150)
Study: 33660386
Drug: Homeopathic Treatment
Normalized name: homeopathic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic Treatment as an Add-On Therapy
Study: 35672726
Drug: Combination condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination condition (30% price increase + information nudge)
Study: 36498690
Drug: Instrument-Assisted Manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrument-Assisted Manual Therapy (IAMT)
Study: 33617382
Drug: Current therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapy satisfaction
Study: 34244006
Drug: RV3 rotavirus
Normalized name: ROTAVIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV3 rotavirus vaccine (Bio Farma) in neonates
Study: 34244006
Drug: RV3 rotavirus
Normalized name: ROTAVIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV3 rotavirus vaccine (Bio Farma) in adults and children
Study: 33600060
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 2 g/kg IVIG once
Study: 32068688
Drug: NT-814 50
Normalized name: NT-219
DrugBank: NT-219 (DB17490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-814 50 mg
Study: 32068688
Drug: NT-814 150
Normalized name: NT-219
DrugBank: NT-219 (DB17490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-814 150 mg
Study: 32068688
Drug: NT-814 300
Normalized name: NT-219
DrugBank: NT-219 (DB17490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-814 300 mg
Study: 34806658
Drug: i.v. lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. lidocaine (1.5 mg/kg later 2 mg/kg/hour)
Study: 32976331
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and visual education with photographs (in-person)
Study: 32976331
Drug: Oral only
Normalized name: TABLET, ORAL ONLY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral only education
Study: 35669353
Drug: Ivermectin 24
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 24 mg (Iv24)
Study: 35669353
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Iv12, Iv24, Control)
Study: 34538402
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Arm C)
Study: 32720552
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment
Study: 35670036
Drug: pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab plus low-dose SNK01 (2 × 10^9 cells/dose)
Study: 39775043
Drug: pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab monotherapy
Study: 33242419
Drug: Amantadine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (up to 100 mg twice daily)
Study: 33242419
Drug: Modafinil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (up to 100 mg twice daily)
Study: 33242419
Drug: Methylphenidate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (up to 10 mg twice daily)
Study: 33588378
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus presleep protein ingestion (40 g intrinsically-labeled casein protein after resistance-type exercise)
Study: 33588378
Drug: Presleep protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presleep protein ingestion (40 g intrinsically L-[1-13C]-phenylalanine and L-[1-13C]-leucine-labeled casein protein)
Study: 34686472
Drug: R-miniCHOP chemoimmunotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-miniCHOP chemoimmunotherapy with oral azacitidine (CC-486)
Study: 34686472
Drug: R-miniCHOP chemoimmunotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-miniCHOP chemoimmunotherapy without oral azacitidine (CC-486)
Study: 33358232
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen/1,000 mg acetaminophen
Study: 33358232
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg codeine/300 mg acetaminophen
Study: 33358232
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hydrocodone/300 mg acetaminophen
Study: 33358232
Drug: Opioids (codeine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids (codeine, hydrocodone, oxycodone)
Study: 36027955
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous amoxicillin and clavulanic acid
Study: 35794079
Drug: HN0037 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HN0037 (10, 30, 60, 120, 200, 300, and 400 mg single doses; 30 and 100 mg once daily for 14 days)
Study: 33337539
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH)
Study: 616406917
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline administered in the same manner)
Study: 35566210
Drug: BCP-SEDDS (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCP-SEDDS (100 mg)
Study: 33387724
Drug: Resveratrol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (400 mg) for 12–14 weeks
Study: 33492303
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg/d for 2 weeks
Study: 34813408
Drug: Low-dose vaginal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vaginal 17β-estradiol tablets
Study: 34264825
Drug: Automated algorithms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated algorithms for predicting lung nodule malignancy from sequential LDCT scans
Study: 33439486
Drug: Fostamatinib as
Normalized name: fostamatinib
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib as second-line therapy
Study: 33439486
Drug: Fostamatinib as
Normalized name: fostamatinib
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib as third-or-later-line therapy
Study: 35940841
Drug: Prescription digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription digital therapeutic (PDT) for mobile-delivered CBT-I (Somryst)
Study: 34658285
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure and exercise
Study: 34658285
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupressure and exercise
Study: 33724592
Drug: Standardized extract
Normalized name: Spring Valley Olive Leaf Standardized Extract 150mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized extract of Opuntia ficus-indica (400 mg/day) for 8 weeks
Study: 35986403
Drug: Tuina treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuina treatment
Study: 34351939
Drug: Prehypertension treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehypertension treatment
Study: 85049646
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg daily for 25 days
Study: 34010843
Drug: Mirabegron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (50 mg once daily)
Study: 35370486
Drug: Propranolol (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (nonselective β-antagonist) administered for 1 week prior to and 4 weeks following HCT
Study: 35370486
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no propranolol treatment)
Study: 32558407
Drug: Escitalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram monotherapy
Study: 33388444
Drug: Etonogestrel subdermal
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etonogestrel subdermal contraceptive implant (SCI)
Study: 35348764
Drug: Polypharmacy (≥5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (≥5 medications)
Study: 35348764
Drug: Excessive polypharmacy
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Excessive polypharmacy (≥10 medications)
Study: 35348764
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medications (PIM)
Study: 35348764
Drug: Nonprescription medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonprescription medications
Study: 35348764
Drug: Potential major
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential major drug-drug interactions (DDI)
Study: 32439189
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin patch (5 mg) applied 1 hour before anesthesia
Study: 32439189
Drug: Topical nitroglycerin
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin patch (5 mg)
Study: 32356581
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TCA) 4 mg
Study: 36273203
Drug: HA-VTE risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-VTE risk probability calculated from a validated VTE risk-prediction model with daily updates and additional review by hematologists for patients with elevated risk (predicted probability of HA-VTE ≥ 0.025)
Study: 32589630
Drug: Vienna Prediction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vienna Prediction Model (VPM) guided anticoagulant treatment
Study: 33336888
Drug: Low-dose glucagon
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucagon (150 μg subcutaneous)
Study: 35147085
Drug: Target-controlled plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target-controlled plasma infusion of lidocaine (3 mg/L) during induction and maintenance of anesthesia
Study: 35866633
Drug: Marburg virus
Normalized name: Marburg virus Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marburg virus vaccine candidates
Study: 33772416
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments
Study: 35426861
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid
Study: 35583217
Drug: Turner syndrome
Normalized name: Syndros
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Turner syndrome patients (TS) with orthodontic treatment
Study: 34813098
Drug: Deep breathing
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep breathing treatment video
Study: 33210302
Drug: Low-dose tocilizumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tocilizumab (40 to 200 mg, with allowance for one repeat dose at 24 to 48 hours)
Study: 35279081
Drug: Guideline-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based therapy with amikacin liposome inhalation suspension
Study: 33439274
Drug: Structured reporting
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured reporting with digital solutions
Study: 33439274
Drug: Standard reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reporting without structured solutions
Study: 34425554
Drug: SC79 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC79 injection at 0.02 mg/kg bodyweight
Study: 34425554
Drug: SC79 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC79 injection at 0.04 mg/kg bodyweight
Study: 33413212
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral care (POC)
Study: 33678517
Drug: Horizons +
Normalized name: Horizant
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Horizons + Group Motivational Enhancement Therapy
Study: 39379540
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics
Study: 33296688
Drug: Higher-dose NOACs
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose NOACs
Study: 33296688
Drug: Lower-dose NOACs
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose NOACs
Study: 34737220
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCS) treatment
Study: 34939318
Drug: Advised to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advised to hand express for 10 minutes twice daily until birth (n=319)
Study: 37944925
Drug: Uterosacral ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral ligament suspension (USLS)
Study: 36030971
Drug: REVASC: 5.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: REVASC: 5.25% NaOCl, saline, and 1 g/mL TAP
Study: 33242163
Drug: Loco-regional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loco-regional treatment (LRT)
Study: 36277940
Drug: Personalized home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized home-based support including monthly visits focused on nutritional counseling and pregnancy monitoring.
Study: 33154182
Drug: Listen-In therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listen-In therapy (self-led therapy app)
Study: 33269836
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (once daily for 10 courses, 6 consecutive times each course) at points Quchi (LI11), Zusanli (ST36), Taichong (LR3), Hegu (LI4), Shenshu (BL23), Geshu (BL17), and Dazhui (GV14)
Study: 33045193
Drug: Oral-fluid HIV
Normalized name: Fluad 2024-2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-fluid HIV self-tests distributed during home visits; one present household member trained on self-test use.
Study: 36244879
Drug: High-dose influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose influenza vaccine (HD)
Study: 32186653
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg of aspirin daily
Study: 32186653
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg of aspirin daily
Study: 35588553
Drug: Placebo intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention (sham analgesic cream) applied before and after heat stimulations
Study: 35093029
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g oral dose of intra-partum azithromycin
Study: 33539944
Drug: Cobimetinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib (60 mg, D3-D23 of each 28-day cycle) plus paclitaxel (80 mg/m2, D1, 8, and 15)
Study: 33539944
Drug: Cobimetinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib plus atezolizumab (840 mg, D1 and D15) and nab-paclitaxel (100 mg/m2, D1, D8, and D15)
Study: 35488544
Drug: Routine diagnosis
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine diagnosis and treatment without vaccine (Control)
Study: 35488544
Drug: HEV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV vaccine (3 doses)
Study: 34274786
Drug: Antidepressants (ATDs)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (ATDs) use for more than 180 days
Study: 34274786
Drug: Antidepressants (ATDs)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (ATDs) use of 180 > cDDD ? 28
Study: 34274786
Drug: Antidepressants (ATDs)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (ATDs) use of cDDD ? 180
Study: 38499358
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen
Study: 33278331
Drug: Wearable Injector
Normalized name: WEARABLE INJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable Injector (WI) delivering 5 mL subcutaneous placebo injections
Study: 36036856
Drug: PL‐ASA (phospholipid‐aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL‐ASA (phospholipid‐aspirin liquid filled capsules)
Study: 36036856
Drug: EC‐ASA (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐ASA (low dose enteric-coated aspirin)
Study: 32023293
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) with dihydroartemisinin-piperaquine and single low-dose primaquine
Study: 32891278
Drug: Peppermint essential
Normalized name: Nature's Truth Peppermint Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint essential oil inhalation
Study: 37245250
Drug: Carvedilol therapy
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol therapy